Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spero Therapeutics (SPRO) EBITDA (2016 - 2025)

Spero Therapeutics (SPRO) has disclosed EBITDA for 10 consecutive years, with -$7.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBITDA rose 60.3% year-over-year to -$7.4 million, compared with a TTM value of -$46.3 million through Sep 2025, down 10300.45%, and an annual FY2024 reading of -$73.4 million, down 421.67% over the prior year.
  • EBITDA was -$7.4 million for Q3 2025 at Spero Therapeutics, down from -$2.4 million in the prior quarter.
  • Across five years, EBITDA topped out at $51.2 million in Q4 2023 and bottomed at -$32.8 million in Q1 2022.
  • Average EBITDA over 5 years is -$8.7 million, with a median of -$14.0 million recorded in 2024.
  • The sharpest move saw EBITDA surged 218.84% in 2021, then crashed 480.12% in 2024.
  • Year by year, EBITDA stood at -$29.2 million in 2021, then soared by 191.56% to $26.8 million in 2022, then soared by 91.22% to $51.2 million in 2023, then crashed by 142.44% to -$21.7 million in 2024, then skyrocketed by 66.02% to -$7.4 million in 2025.
  • Business Quant data shows EBITDA for SPRO at -$7.4 million in Q3 2025, -$2.4 million in Q2 2025, and -$14.7 million in Q1 2025.